Development of Analytical Method for the Determination of a New Antifilarial Drug, CDR 101 in Body Fluids and Its Application in Pharmacokinetic and Clinical Studies.
| dc.contributor.author | Selvamuniandy, Tamil Selvy | |
| dc.date.accessioned | 2018-07-19T03:18:15Z | |
| dc.date.available | 2018-07-19T03:18:15Z | |
| dc.date.issued | 1997-04 | |
| dc.description.abstract | CDR 101 is a new anti filarial drug which was selected from screening under the 01'<TIP/World Bank/WHO Drug Discovery Programme. Information on the physicochemical and pharmacokinetic properties are unavailable. The objective of this study is to address these issues. CDR 101 decomposes at 238 - 240 °C with pJ(a values of5.28 ± 0.31 and 7.49 ± 0.34. It is sensitive towards light. CDR 101 in plasma is stable at -20 and -70 °C but not at 4 °C. A selective and sensitive highperformance liquid chromatographic assay for quantitative determination of CDR 101 is described. After extraction from plasma and blood using chloroform, CDR 101 was analysed using a C18 Nucleosil ODS-2 reverse-phase stainlees steel column and a mobile phase of acetonitrile-0.05 M ammonium acetate adjusted to pH 3.0 with ultraviolet detection at 318 nm. The mean recoveries of CDR 101 in plasma and blood over a concentration range of25- 500 ng/mL were 95.51 ± 2.01% and 83.35 ± 1.87%, respectively. The within-day and day-to-day coefficients of variations for plasma were 3.23%- 6.21% and 2.59%- 9.90% respectively whereas for blood were 2.89 - 5.92% and 2.89 - 6.82% respectively. The minimum detectable concentration for CDR 101 in plasma and blood were 1 ng/mL and 2.5 ng/mL respectively. This method was found to be suitable for clinical pharmacokinetic studies in rats and calves. Following intravenous administration of a dose of 0.4 mg/kg in rats, CDR 101 was eliminated from blood with half-life (t 112), clearance(Cl) and volume of distribution (Vd) of 84.7 ± 21.5 min, 69.8 ± 14.4 mL/min/kg and 8.6 ± 3.2 L/kg, respectively. In calves treated subcutaneously, the pharmacokinetic parameters could not be calculated due to erratic absorption.. No metabolite peaks were observed in any of the three pharmacokinetic studies. | en_US |
| dc.identifier.uri | http://hdl.handle.net/123456789/5972 | |
| dc.subject | Antifilarial Drug | en_US |
| dc.title | Development of Analytical Method for the Determination of a New Antifilarial Drug, CDR 101 in Body Fluids and Its Application in Pharmacokinetic and Clinical Studies. | en_US |
| dc.type | Thesis | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: